Stock Events

Stock Events

AgeX Therapeutics 

$11.1
26
-$1.5-11.9% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Oct 7
$0.2
Jul 7
$0.2
Apr 7
$0.2
Jan 7
$0.2
Oct 6
$0.2
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19MayExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.66
-0.54
-0.43
-0.31
Expected EPS
-0.44
Actual EPS
N/A

Financials

-10,424.65%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
142,000Revenue
-14.8MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that could directly compete with AgeX's regenerative medicine and cellular therapy approaches.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, making it a direct competitor in developing therapies that could overlap with AgeX's focus on age-related diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing in the same space as AgeX by targeting genetic diseases and conditions.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing with AgeX in the development of novel therapies for genetic conditions.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, potentially competing with AgeX in the market for therapies targeting age-related diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with AgeX in the field of molecular biology and therapy development for various conditions.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics is advancing the field of CRISPR-based genetic and cellular therapies, which could compete with AgeX's therapeutic approaches.
Voyager Therapeutics
VYGR
Mkt Cap259.04M
Voyager Therapeutics focuses on the development of gene therapies for neurodegenerative diseases, potentially competing with AgeX's focus on age-related conditions.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is working on programmed cellular immunotherapies for cancer and immune disorders, which could compete with AgeX's approach to regenerative medicine and cellular therapies.

About

Health Technology
Pharmaceuticals: Major
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
Show more...
CEO
Michael West
Employees
5
Country
US
ISIN
US00848H1086
WKN
000A2N8PC

Listings

XASE
US
SER
F
DE
2BO.F
BOATS
BOATS
SER.BOATS

0 Comments

Share your thoughts

FAQ

What is AgeX Therapeutics stock price today?▼
The current price of AGE is $11.1 USD — it has decreased by -11.9% in the past 24 hours. Watch AgeX Therapeutics stock price performance more closely on the chart.
What is AgeX Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AgeX Therapeutics stocks are traded under the ticker AGE.
What is AgeX Therapeutics revenue for the last year?▼
AgeX Therapeutics revenue for the last year amounts to 142,000 USD.
What is AgeX Therapeutics net income for the last year?▼
AGE net income for the last year is -14.8M USD.
Does AgeX Therapeutics pay dividends?▼
Yes, AGE dividends are paid quarterly. The last dividend per share was 0.2 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does AgeX Therapeutics have?▼
As of April 01, 2026, the company has 5 employees.
In which sector is AgeX Therapeutics located?▼
AgeX Therapeutics operates in the Professional, Scientific, and Technical Services sector.
When did AgeX Therapeutics complete a stock split?▼
AgeX Therapeutics has not had any recent stock splits.
Where is AgeX Therapeutics headquartered?▼
AgeX Therapeutics is headquartered in Alameda, US.